氯美噻唑乙烷-1,2-二磺酸酯 | 1867-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 氯美噻唑乙烷-1,2-二磺酸酯
• 中文别名: 乙二磺酸氯美噻唑
• 英文名称: Heminevrin (TN)
• 英文别名: 5-(2-chloroethyl)-4-methyl-1,3-thiazole;ethane-1,2-disulfonic acid
• CAS: 1867-58-9
• 化学式: C8H14ClNO6S3
• 分子量: 351.9
• InChiKey: DRSIVJKCYUTEEE-UHFFFAOYSA-N

物化性质

• 熔点：
  124°

计算性质

• 辛醇/水分配系数(LogP)：
  0.99
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  167
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 海关编码：
  2934100090

制备方法与用途

类别

有毒物质

毒性分级

中毒

急性毒性

口服-小鼠 LD50: 835 毫克/公斤; 皮下-小鼠 LD50: 620 毫克/公斤

可燃性危险特性

0可燃, 火场释放有毒氯化物, 氮氧化物, 硫氧化物烟雾

储运特性

库房低温通风干燥

灭火剂

水, 二氧化碳, 泡沫, 沙土

文献信息

• NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110275603A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了脱氢鸟苷酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善疾病或障碍的方法，其中已知抑制脱氢鸟苷酸脱氢酶具有益处效果。
• [EN] NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS IMMUNOMODULATEURS ET ANTI-INFLAMMATOIRES
  申请人：INCOZEN THERAPEUTICS PVT LTD

  公开号：WO2011138665A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors of formula (I), methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了式(I)的脱氢二氢乳酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善已知抑制二氢乳酸脱氢酶显示有益效果的疾病或疾病的方法。
• [EN] AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE AZABIPHÉNYLAMINOBENZOÏQUE COMME INHIBITEURS DE LA DHODH
  申请人：ALMIRALL LAB

  公开号：WO2009021696A1

  公开（公告）日：2009-02-19

  New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH).

  揭示了具有化学结构式(I)的新的阿扎比苯胺基苯甲酸衍生物；以及它们的制备过程、包含它们的药物组合物以及它们在治疗中作为脱氢乳酸脱氢酶（DHODH）抑制剂的用途。
• Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
  申请人：Almirall, S.A.

  公开号：EP2228367A1

  公开（公告）日：2010-09-15

  The present invention is directed to novel water-soluble pharmaceutically acceptable, crystalline addition salts of (i) an amine containing one or more hydroxyl and/or carboxylic groups with (ii) amino nicotinic acid derivatives of formula (I) wherein Ra, Rb, Rc and Rd independently represent groups selected from hydrogen atoms, halogen atoms, C1-4 alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C1-4 alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and pharmaceutically acceptable solvates thereof.

  该发明涉及一种新型水溶性药用可接受的结晶加合盐，该盐包括(i)含有一个或多个羟基和/或羧基的胺与(ii)式(I)的氨基烟酸衍生物之间的结合，其中Ra、Rb、Rc和Rd独立地表示从氢原子、卤原子、可能被1、2或3个卤原子和羟基选择的C1-4烷基组成的基团，以及可能被1、2或3个卤原子和羟基选择的C1-4烷氧基组成的基团，以及其药用可接受的溶剂化合物。
• [EN] ADDITION SALTS OF TROMETHAMINE WITH AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS<br/>[FR] SELS D'ADDITION DE TROMÉTHAMINE AVEC DES DÉRIVÉS D'ACIDE AZABIPHÉNYLAMINOBENZOÏQUE COMME INHIBITEURS DE DHODH
  申请人：ALMIRALL SA

  公开号：WO2010102825A1

  公开（公告）日：2010-09-16

  The present invention is directed to novel crystalline addition salts of (i) tromethamine with (ii) an azabiphenylaminobenzoic acid derivatives of formula (I) wherein R1 is selected from the group consisting of C1-C4 alkyl, C3-C4 cycloalkyl and -CF3, G1 is selected from nitrogen atoms and CH, C(CH3) and C(CF3) groups, and G2 represents a phenyl group optionally substituted with one or two substituents selected from chloro, fluoro, methoxy, ethoxy, isopropoxy, trifluoromethoxy, CF3, and -CONR7R8, wherein R7 is hydrogen and R8 is cyclopropyl or R7 and R8 together with the nitrogen atom to which they are attached form a group of formula (IA) wherein n is 1. and pharmaceutically acceptable solvates thereof.

  本发明涉及一种新的晶体加合物盐，其由式(I)中的一种含有氮杂双苯基氨基苯甲酸衍生物与三甲醇胺的加合物组成，其中R1选择自C1-C4烷基，C3-C4环烷基和-CF3的群组中，G1选择自氮原子和CH，C(CH3)和C( )基团，G2代表一个苯基，该苯基可选地被氯，氟，甲氧基，乙氧基，异丙氧基，三氟甲氧基， 和-CONR7R8中的一个或两个取代基取代，其中R7为氢，R8为环丙基或R7和R8与它们所连接的氮原子一起形成式(IA)的基团，其中n为1，以及其药学上可接受的溶剂化物。